Rituximab and mycophenolate for scleroderma lung disease
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with systemic sclerosis (scleroderma) by a doctor using the 2013 criteria.
- Your lung disease from scleroderma is either severe, or at high risk of getting worse, or has clearly worsened in the last 6-24 months.
- You are eligible to start treatment with mycophenolate mofetil (CellCept) for your lung disease.
- You have not had rituximab or mycophenolate before for this condition.
- You do not have other significant lung diseases (like asthma, cystic fibrosis, or idiopathic pulmonary fibrosis) or severe heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether rituximab can slow worsening lung scarring (interstitial lung disease) when there is an inflammatory component. You would get rituximab or a placebo (inactive treatment) in a blinded, randomized design to compare safety and effectiveness.
This Phase 2 study tests whether mycophenolate mofetil (MMF) can slow or improve early, mild lung scarring in people with systemic sclerosis. It’s meant for systemic sclerosis patients who have lung involvement on a CT scan but still have good breathing test results.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
This trial tests whether a special type of stem cells from umbilical cords can help people with scleroderma-related lung disease that is getting worse. You may qualify if your lung function has declined despite current treatments.
Hear when a new Interstitial Lung Disease With Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.